International journal of cardiology · 2025
Interleukin-1 blockade in patients with ST-segment elevation myocardial infarction with and without history of coronary artery disease.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lopez Rocio I, Morello Matteo, Golino Michele, Hogwood Austin C, Marchetta Michele, Del Buono Marco G, Moroni Francesco, Mbualungu James, Agatiello Carla R, Van Tassell Benjamin W, Abbate Antonio
Аннотация
BACKGROUND: Patients with a history of coronary artery disease (CAD) presenting with ST-elevation myocardial infarction (STEMI) have high risk. We aimed to determine whether patients with CAD history presenting with STEMI had greater systemic inflammation and/or whether they benefitted similarly from IL-1 blockade.
METHODS: We pooled data from three randomized clinical trials, including 139 patients with STEMI treated with anakinra or placebo. Patients were stratified by history of CAD defined as prior documented CAD, MI or coronary revascularization. The area under the curve (AUC) for C-reactive protein (CRP) was used to assess systemic inflammation. Event-free survival defined as the time from enrollment to the occurrence of a predefined adverse outcome, including new-onset heart failure, hospitalization for heart failure, or death, was compared using Cox regression analysis.
RESULTS: Of the 139 patients, 113 (81 %) had no history of CAD, while 26 (19 %) had a history of CAD. The CRP-AUC was significantly lower in the anakinra group compared placebo, independent of history of CAD: 85 [47-137] vs. 349 [154-580] mg·day/L for anakinra and placebo, respectively, in patients with history of CAD, and 86 [43-179] vs. 213 [115-341] mg·day/L in patients without CAD history; p for interaction = (0.27). No significant interactions were found between history of CAD and treatment allocation for the composite outcome for patients with and without history of CAD, respectively, p for interaction = (0.48).
CONCLUSION: IL-1 blockade with anakinra in STEMI leads to similar reductions in systemic inflammation and improvement in HF-related outcomes inpatients both with and without history of CAD.
METHODS: We pooled data from three randomized clinical trials, including 139 patients with STEMI treated with anakinra or placebo. Patients were stratified by history of CAD defined as prior documented CAD, MI or coronary revascularization. The area under the curve (AUC) for C-reactive protein (CRP) was used to assess systemic inflammation. Event-free survival defined as the time from enrollment to the occurrence of a predefined adverse outcome, including new-onset heart failure, hospitalization for heart failure, or death, was compared using Cox regression analysis.
RESULTS: Of the 139 patients, 113 (81 %) had no history of CAD, while 26 (19 %) had a history of CAD. The CRP-AUC was significantly lower in the anakinra group compared placebo, independent of history of CAD: 85 [47-137] vs. 349 [154-580] mg·day/L for anakinra and placebo, respectively, in patients with history of CAD, and 86 [43-179] vs. 213 [115-341] mg·day/L in patients without CAD history; p for interaction = (0.27). No significant interactions were found between history of CAD and treatment allocation for the composite outcome for patients with and without history of CAD, respectively, p for interaction = (0.48).
CONCLUSION: IL-1 blockade with anakinra in STEMI leads to similar reductions in systemic inflammation and improvement in HF-related outcomes inpatients both with and without history of CAD.